ACR Meeting Abstracts

ACR Meeting Abstracts

  • Meetings
    • ACR Convergence 2024
    • ACR Convergence 2023
    • 2023 ACR/ARP PRSYM
    • ACR Convergence 2022
    • ACR Convergence 2021
    • ACR Convergence 2020
    • 2020 ACR/ARP PRSYM
    • 2019 ACR/ARP Annual Meeting
    • 2018-2009 Meetings
    • Download Abstracts
  • Keyword Index
  • Advanced Search
  • Your Favorites
    • Favorites
    • Login
    • View and print all favorites
    • Clear all your favorites
  • ACR Meetings

2015 ACR/ARHP Annual Meeting

November 6-11, 2015. San Francisco, CA.

View by Number View by Title View Sessions
View by Date

Tuesday, November 10, 2015

4:30PM-6:00PM
Abstract Number: 6L
Effect of Interleukin-17A Inhibition on Spinal Radiographic Changes through 2 Years in Patients with Active Ankylosing Spondylitis: Results of a Phase 3 Study with Secukinumab
ACR Late-breaking Abstract Session
4:30PM-6:00PM
Abstract Number: 3219
Efficacy and Safety of 4 Weeks Administration of Arsenic Trioxide in Moderate Active Systemic Lupus Erythematosus. a Phase I/II Proof-of-Concept Sequential Dose Escalation Multicenter Study
Systemic Lupus Erythematosus - Clinical Aspects and Treatment VI: Novel Therapies
4:30PM-6:00PM
Abstract Number: 4L
Efficacy and Safety of Epratuzumab in Patients with Moderate-to-Severe Systemic Lupus Erythematosus: Results from Two Phase 3 Randomized, Placebo-Controlled Trials
ACR Late-breaking Abstract Session
4:30PM-6:00PM
Abstract Number: 3189
Enhancement of Mitochondrial Biogenesis Inhibits Cell Proliferation and MMP-3/RANKL Secretion in Rheumatoid Arthritis Fibroblast-like Synovial Cells and Joint Destruction in Arthritis Model Mice
Rheumatoid Arthritis Animal Models II
4:30PM-6:00PM
Abstract Number: 3166
Epistatic Interaction of Functional Inflammasome Genetic Variants in Determining the Risk of Gout
Metabolic and Crystal Arthropathies II: Mechanisms and Associations
4:30PM-6:00PM
Abstract Number: 3210
Evaluation of Sacroiliac Joint Radiographs in Patients with Chronic Low Back Pain: Is Erosion the Main Driver of Interreader Disagreement?
Spondylarthropathies and Psoriatic Arthritis - Clinical Aspects and Treatment: Clinical Aspects, Imaging and Biomarkers
4:30PM-6:00PM
Abstract Number: 3235
Factors Associated with Nonadherence to Recently Initiated Disease-Modifying Antirheumatic Drugs
ARHP IV: Clinical Practice and Patient Care
4:30PM-6:00PM
Abstract Number: 3186
Foot Synovitis in Patients with Rheumatoid Arthritis in Apparent Remission Is Associated with Unstable Remission Status, Radiographic Progression and Worse Long-Term Functional Outcomes
Rheumatoid Arthritis - Clinical Aspects V: Goal = Remission
4:30PM-6:00PM
Abstract Number: 3202
Functional Anti-Muscarinic Receptor-3 Monoclonal Antibodies Derived from Salivary Gland in Patients of Sjögren’s Syndrome
Sjögren's Syndrome II: Clinical Discoveries
4:30PM-6:00PM
Abstract Number: 3182
High Body Mass Index Negatively Impacts Time to Achieving Sustained Remission in Early Rheumatoid Arthritis: Results from a Multicenter Early Arthritis Cohort Study
Rheumatoid Arthritis - Clinical Aspects V: Goal = Remission
4:30PM-6:00PM
Abstract Number: 3181
How Common Is Inactive Disease in a Prospective Cohort of Patients with Juvenile Idiopathic Arthritis? the Importance of Definition
Pediatric Rheumatology - Clinical and Therapeutic Aspects IV: Imaging and Novel Clinical Interventions
4:30PM-6:00PM
Abstract Number: 3168
How Strong Cardiovascular Risk Factor Are Gouty Tophi?
Metabolic and Crystal Arthropathies II: Mechanisms and Associations
4:30PM-6:00PM
Abstract Number: 3204
Hypoechoic Lesions on Parotid Gland Ultrasound Are a Surrogate Marker of Focal Lymphocytic Sialadenitis on Minor Salivary Gland Biopsy in Sjögren’s Syndrome
Sjögren's Syndrome II: Clinical Discoveries
4:30PM-6:00PM
Abstract Number: 3227
Identification of Novel Protein-Coding Genetic Variants Associated with Takayasu Arteritis
Vasculitis IV
4:30PM-6:00PM
Abstract Number: 3201
IL-7 Drives Cytokine Secretion of IL-7Rabright CCR9-Expressing T-Follicular Helper-like Cells: Potential New Axis in Lymphoid Neogenesis in Salivary Glands of Primary Sjogren s Syndrome Patients
Sjögren's Syndrome II: Clinical Discoveries
  • «Previous Page
  • 1
  • …
  • 66
  • 67
  • 68
  • 69
  • 70
  • …
  • 72
  • Next Page»
Advanced Search

Your Favorites

You can save and print a list of your favorite abstracts during your browser session by clicking the “Favorite” button at the bottom of any abstract. View your favorites »

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].

Wiley

  • Online Journal
  • Privacy Policy
  • Permissions Policies
  • Cookie Preferences

© Copyright 2025 American College of Rheumatology